Literature DB >> 24325315

Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus.

Jung Il Lee1, Ja Kyung Kim, Hye Young Chang, Jin-Woo Lee, Joon Mee Kim, Hyun Jung Chung, Young Soo Kim, Kwan Sik Lee.   

Abstract

BACKGROUND AND AIM: Hepatitis B virus (HBV) replication detected before the resection of hepatocellular carcinoma (HCC) is to be controlled by antiviral agents. However, management strategy for patients with preoperatively undetectable HBV DNA without antiviral therapy is not clearly delineated. This study investigated viral reactivation after the liver resection in non-replicating HBV DNA-related HCC patients and its impact on the surgical outcome.
METHODS: From 198 patients that underwent liver resection due to HBV-related HCC, 101 patients who had serially checked serum HBV DNA were analyzed.
RESULTS: From 101 patients, 33 patients had baseline undetectable HBV DNA. Eleven patients (11/33, 33.3%) had viral replication after the liver resection. The postoperative viral reactivation (HR: 2.144; 95% CI: 1.122-4.097; P = 0.021), along with the existence of satellite nodules (HR: 3.034; 95% CI: 1.1.376-6.689; P = 0.006), existence of microvascular invasion (HR: 2.479; 95% CI: 1.303-4.718; P = 0.006), and HBeAg positivity (HR: 2.059; 95% CI: 1.155-3.670; P = 0.014) predicted recurrence after the surgery. Quantification of intrahepatic total and covalently closed circular DNA (cccDNA) was done in 14 patients whose baseline serum HBV DNA was undetectable without the use of antiviral agent. Amount of intrahepatic cccDNA expressed as copies/hepatocyte in patients with postoperative viral reactivation showed significantly higher than those in patients with sustained negative serum HBV DNA (P = 0.010).
CONCLUSIONS: This study shows that naturally suppressed preoperative HBV without application of antiviral agent does not ensure undetectable serum HBV after the surgery, and postoperative viral reactivation might be associated with HCC recurrence.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  covalently closed circular DNA; hepatitis B virus; hepatocellular carcinoma; prognosis; virus replication

Mesh:

Substances:

Year:  2014        PMID: 24325315     DOI: 10.1111/jgh.12472

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  3 in total

1.  Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B?

Authors:  Clifford Akateh; Timothy M Pawlik; Jordan M Cloyd
Journal:  Ann Transl Med       Date:  2018-10

2.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2022-04-01

3.  Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis.

Authors:  Kai-Xuan Liu; Jian-Guo Hong; Rui Wu; Zhao-Ru Dong; Ya-Fei Yang; Yu-Chuan Yan; Chun-Cheng Yang; Lun-Jie Yan; Sheng-Yu Yao; Hai-Chao Li; Xu-Ting Zhi; Tao Li
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.